ChiCTR2400087600 版本V1.0 版本创建时间2024/07/31 09:28:02 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400087600 

最近更新日期:

Date of Last Refreshed on:

2024-07-31 09:27:59 

注册时间:

Date of Registration:

2024-07-31 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

脑桥前池吗啡泵植入术缓解癌性疼痛的技术应用与推广

Public title:

The application and promotion of the technique of pump implantation for morphine into the prepontine cistern for alleviating cancer pain

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脑桥前池吗啡泵植入术缓解癌性疼痛的技术应用与推广

Scientific title:

The application and promotion of the technique of pump implantation for morphine into the prepontine cistern for alleviating cancer pain

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

肖艳英 

研究负责人:

王亚平 

Applicant:

Yanying Xiao 

Study leader:

Yaping Wang 

申请注册联系人电话:

Applicant telephone:

+86 134 6760 9491

研究负责人电话:

Study leader's
telephone:

+86 136 0731 4476

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xiaoyanying192@csu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

wangyaping6568@csu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省长沙市芙蓉区人民中路139号

研究负责人通讯地址:

湖南省长沙市芙蓉区人民中路139号

Applicant address:

139 Renmin Middle Road, Furong District, Changsha, China

Study leader's address:

139 Renmin Middle Road, Furong District, Changsha, China

申请注册联系人邮政编码:

Applicant postcode:

410011

研究负责人邮政编码:

Study leader's postcode:

410011

申请人所在单位:

中南大学湘雅二医院

Applicant's institution:

The Second Xiangya hospital, Central South University

研究负责人所在单位:

中南大学湘雅二医院

Affiliation of the Leader:

The Second Xiangya hospital, Central South University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2023)K071

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中南大学湘雅二医院伦理委员会

Name of the ethic committee:

Ethics Committee of The Second Xiangya Hospital of Central South University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-09-13 00:00:00

伦理委员会联系人:

陈晋东

Contact Name of the ethic committee:

Jin-Dong Chen

伦理委员会联系地址:

湖南省长沙市人民中路139号

Contact Address of the ethic committee:

No.139 Renmin Middle Road, Changsha, Hunan, China.

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 731 8529 2476

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xy2gcpjiang@163.com

研究实施负责(组长)单位:

中南大学湘雅二医院

Primary sponsor:

The Second Xiangya hospital, Central South University

研究实施负责(组长)单位地址:

湖南省长沙市芙蓉区人民中路139号

Primary sponsor's address:

139 Renmin Middle Road, Furong District, Changsha, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南

市(区县):

长沙市

Country:

China

Province:

hunan

City:

Changsha

单位(医院):

中南大学湘雅二医院

具体地址:

湖南省长沙市芙蓉区人民中路139号

Institution
hospital:

The Second Xiangya hospital, Central South University

Address:

139 Renmin Middle Road, Furong District, Changsha, China

国家:

中国

省(直辖市):

湖南

市(区县):

长沙

Country:

China

Province:

Hunan

City:

Changsha

单位(医院):

湖南省人民医院

具体地址:

湖南省长沙市芙蓉区解放西路61号

Institution
hospital:

Hunan Provincial People's Hospital

Address:

No. 61, Jiefang West Road, Furong District, Changsha, Hunan Province, China

国家:

中国

省(直辖市):

湖南

市(区县):

岳阳

Country:

China

Province:

Hunan

City:

Yueyang

单位(医院):

岳阳市中医院

具体地址:

湖南省岳阳市岳阳楼区枫桥湖路269号

Institution
hospital:

Yueyang Hospital of Traditional Chinese Medicine

Address:

No.269 Fengqiao Lake Road, Yueyanglou District, Yueyang City, Hunan Province, China

国家:

中国

省(直辖市):

湖南

市(区县):

衡阳

Country:

China

Province:

Hunan

City:

Hengyang

单位(医院):

南华大学附属第二医院

具体地址:

湖南省衡阳市蒸湘区解放大道35号

Institution
hospital:

The Second Affiliated Hospital of Nanhua University

Address:

No.35 Jiefang Avenue, Steixiang District, Hengyang City, Hunan Province, China

国家:

中国

省(直辖市):

湖南

市(区县):

郴州

Country:

China

Province:

hunan

City:

Chenzhou

单位(医院):

郴州市第一人民医院

具体地址:

湖南省郴州市北湖区罗家井102号

Institution
hospital:

Chenzhou First People's Hospital

Address:

No. 102, Luo Jiajing, Beihu District, Chenzhou City, Hunan Province, China

国家:

中国

省(直辖市):

河南省

市(区县):

郑州

Country:

China

Province:

Henan

City:

Zhengzhou

单位(医院):

河南省肿瘤医院

具体地址:

河南省郑州市金水区东明路127号.

Institution
hospital:

Henan Provincial Tumor Hospital

Address:

No.127 Dongming Road, Jinshui District, Zhengzhou City, Henan Province, China.

国家:

中国

省(直辖市):

黑龙江

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Haerbin

单位(医院):

哈尔滨医科大学附属第四医院

具体地址:

The Fourth Hospital of Harbin Medical University

Institution
hospital:

The Fourth Hospital of Harbin Medical University

Address:

No. 37, Yiyuan Street, Nangang District, Harbin, Heilongjiang Province

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Changsha

单位(医院):

四川省肿瘤医院

具体地址:

四川省成都市人民南路四段55号

Institution
hospital:

Sichuan Provincial Tumor Hospital

Address:

No. 55, Section 4, Renmin South Road, Chengdu, Sichuan, China

国家:

中国

省(直辖市):

上海

市(区县):

上海

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海复旦大学中山医院

具体地址:

上海市徐汇区枫林路180号

Institution
hospital:

Zhongshan Hospital, Fudan University, Shanghai

Address:

180 Fenglin Road, Xuhui District, Shanghai, China

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

癌性疼痛  

Target disease:

carcinogenic pain

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

探讨经腰骶入路脑桥前池吗啡泵植入技术治疗头面部癌痛、全身多处转移性癌痛的临床疗效及安全性  

Objectives of Study:

To investigate the clinical efficacy and safety of morphine pump implantation technique in the prepontine cistern via lumbosacral approach for the treatment of head and face cancer pain and systemic multiple metastatic cancer pain.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

① 符合癌性疼痛诊断的原发或转移头颈癌患者且常规疼痛管理没有效果(≥200mg/d吗啡或等效药物口服无效)或有无法耐受的副反应; ② 符合鞘内植入吗啡泵手术指征者; ③ 数字疼痛量表NRS≥6分(满分10分); ④ 年龄≥18岁。

Inclusion criteria

① Patients with primary or metastatic head and neck cancer who meet the diagnosis of cancer pain and conventional pain management is ineffective (≥200mg/d morphine or its equivalent is ineffective orally) or have intolerable side effects; ② Those who meet the surgical indications for intrathecal implantation of morphine pump; ③ NRS score ≥ 6 (out of 10) on the Digital Pain Scale; ④ Age ≥ 18 years old.

排除标准:

① 合并全身严重感染、脑脊液循环障碍、安装心脏起搏器者; ② 神志不清 , 无法描述自身身体感受 , 无法配合治疗; ③ 不能耐受麻醉及吗啡泵植入手术,如严重的心、肺、肝等主要脏器功能不全或严重凝血功能障碍; ④ 对于研究使用药物过敏表现者。

Exclusion criteria:

① Combined with serious systemic infections, cerebrospinal fluid circulation disorders, the installation of pacemakers; ② Confused, unable to describe their own physical sensations, unable to cooperate with the treatment; ③ Inability to tolerate anesthesia and morphine pump implantation surgery, such as severe heart, lung, liver and other major organ insufficiency or severe coagulation disorders; (iv) Those who are allergic to the drugs used in the study.

研究实施时间:

Study execute time:

From 2024-08-05 00:00:00 To 2025-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-05 00:00:00 To 2025-08-31 00:00:00

干预措施:

Interventions:

组别:

脑桥前池组

样本量:

80

Group:

prepontine cistern group

Sample size:

干预措施:

脑桥前池吗啡泵置入,进行疼痛管理

干预措施代码:

Intervention:

Morphine pump placement in the prepontine cistern for pain management

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

hunan

City:

Changsha

单位(医院):

中南大学湘雅二医院 

单位级别:

三甲 

Institution
hospital:

The Second Xiangya hospital, Central South University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

长沙 

Country:

China

Province:

hunan

City:

Changsha

单位(医院):

湖南省人民医院 

单位级别:

三甲 

Institution
hospital:

Hunan Provincial People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

Hunan 

市(区县):

岳阳 

Country:

China

Province:

hunan

City:

Yueyang

单位(医院):

岳阳市中医院 

单位级别:

三甲 

Institution
hospital:

Yueyang Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南省 

市(区县):

衡阳市 

Country:

China

Province:

hunan

City:

Hengyang

单位(医院):

南华大学附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Nanhua University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

湖南 

市(区县):

郴州市 

Country:

China

Province:

hunan

City:

Chenzhou

单位(医院):

郴州市第一人民医院 

单位级别:

三甲 

Institution
hospital:

Chenzhou First People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

河南省 

市(区县):

郑州 

Country:

China

Province:

henan

City:

Zhengzhou

单位(医院):

河南省肿瘤医院 

单位级别:

三甲 

Institution
hospital:

Henan Provincial Tumor Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

黑龙江省 

市(区县):

哈尔滨市 

Country:

China

Province:

Heilongjiang

City:

Haerbin

单位(医院):

哈尔滨医科大学附属第四医院 

单位级别:

三甲 

Institution
hospital:

The Fourth Hospital of Harbin Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

四川省 

市(区县):

成都 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川省肿瘤医院 

单位级别:

三甲 

Institution
hospital:

Sichuan Provincial Tumor Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

上海 

市(区县):

上海 

Country:

China

Province:

Shanghai

City:

Shanghai

单位(医院):

上海复旦大学中山医院 

单位级别:

三甲 

Institution
hospital:

Zhongshan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

疼痛数字评分

指标类型:

主要指标

Outcome:

The numerical rating scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

爆发痛

指标类型:

主要指标

Outcome:

roburst pain

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

口服镇痛药物剂量

指标类型:

次要指标

Outcome:

Dosage of oral analgesics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

吗啡泵镇痛药物剂量

指标类型:

次要指标

Outcome:

Morphine pump analgesic drug dosage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量评分

指标类型:

次要指标

Outcome:

Quality of Life Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

副反应发生情况

指标类型:

副作用指标

Outcome:

Occurrence of adverse events

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

CT、MRI等影像学检查结果

指标类型:

次要指标

Outcome:

CT, MRI and other imaging findings

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生存时间

指标类型:

次要指标

Outcome:

survival time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

根据试验进展,预计2026年1月以后,使用ResMan (www.medresman.org) 管理数据管理与共享。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Based on the progress of the trial, it is expected that after January 2026, data management and sharing will be managed using ResMan (www.medresman.org).

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-07-31 09:27:59